A Randomized, Multicenter, Phase 2 Study of DSP-
7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy (BBI-DSP7888-201G), NCT03149003
PURPOSE OF THE CLINICAL RESEARCH TRIAL:
This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.
MORE DETAILS ON THIS TRIAL:
17058 / NCT03149003 / Re-Open 7/30/19